Unknown

Dataset Information

0

Replication-associated mechanisms contribute to an increased CpG > TpG mutation burden in mismatch repair-deficient cancers

ABSTRACT:

SUBMITTER: Ward J 

PROVIDER: S-EPMC12376743 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
| S-EPMC9226910 | biostudies-literature
Unknown Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability.
| S-EPMC7697596 | biostudies-literature
Unknown T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
| S-EPMC8201475 | biostudies-literature
Unknown Stepwise deletions of polyA sequences in mismatch repair-deficient colorectal cancers.
| S-EPMC1891934 | biostudies-literature
Unknown A Family of Rhodium Complexes with Selective Toxicity toward Mismatch Repair-Deficient Cancers.
| S-EPMC5965675 | biostudies-literature
Unknown Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting.
| S-EPMC10064478 | biostudies-literature
Unknown Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.
| S-EPMC3753890 | biostudies-literature
Unknown Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
| S-EPMC10690097 | biostudies-literature
Unknown Integrating Tumor Sequencing Into Clinical Practice for Patients With Mismatch Repair-Deficient Lynch Syndrome Spectrum Cancers.
| S-EPMC8373535 | biostudies-literature
Unknown Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
| S-EPMC11108776 | biostudies-literature